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ABSTRACT
Background: Despite suppressive antiretroviral therapy (ART), many HIV-infected individuals have low-level persistent
immune activation in the central nervous system (CNS). There have been concerns regarding the CNS efficacy of tenofovir
alafenamide fumarate (TAF) because of its low cerebrospinal fluid (CSF) concentrations and because it is a substrate of the
active efflux transporter P-glycoprotein. Our aim was to investigate whether switching from emtricitabine (FTC)/tenofovir
disoproxil fumarate (TDF) or abacavir (ABC)/lamivudine (3TC) to FTC/TAF would lead to changes in residual intrathecal
immune activation, viral load, or neurocognitive function.
Methods: Twenty HIV-1-infected neuro-asymptomatic adults (11 on ABC/3TC and 9 on FTC/TDF) were included in this pro-
spective study. At baseline, all participants changed their nucleoside analogues to FTC/TAF without any other changes in
their ART regimen. We performed lumbar punctures, venipunctures, and neurocognitive testing at baseline and after three
and 12months.
Results: During follow-up, there were no significant changes in CSF or plasma HIV RNA, CSF neopterin, CSF b2-microglobu-
lin, IgG index, albumin ratio, CSF NFL, or neurocognitive function in assessed by Cogstate in any of the groups.
Conclusion: This small pilot study indicates that switching to FTC/TAF from ABC/3TC or FTC/TDF has neither a positive,
nor a negative effect on the HIV infection in the CNS.
 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
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Introduction
Shortly after transmission, HIV establishes a chronic
infection in the central nervous system (CNS), mainly
within macrophages and microglial cells, with accompa-
nying immune activation [1–3]. Antiretroviral treatment
(ART) effectively suppresses viral replication in blood as
well as in cerebrospinal fluid (CSF) in most individuals
[4]. The degree of cellular immune activation in the CNS
can be determined by quantifying CSF biomarkers such
as white blood cell count (WBC), neopterin (a marker of
macrophage activation mainly), and b2-microglobulin
(part of the major histocompatibility complex class I
molecule). ART also reduces the immune activation and
inflammatory response in CNS [5,6]. We have previously
found an association between CNS inflammation and
HIV-induced axonal injury as measured by CSF concen-
trations of the light subunit of neurofilament protein
(NFL) [7]. CSF NFL concentrations are highest in individu-
als with HIV-associated dementia (HAD) where axonal
damage and loss is prominent, but elevated levels can
also be found in untreated individuals with low CD4þ T-
cell counts without neurocognitive symptoms [8–12].
Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
and abacavir/lamivudine (ABC/3TC) have been the most
widely used nucleoside reverse transcriptase inhibitor
(NRTI) combinations for several years [13]. In 2015, when
this study was initiated, a new prodrug of tenofovir,
tenofovir alafenamide fumarate (TAF), was introduced.
The older prodrug TDF is converted to tenofovir in
blood, taken up intracellularly, and then phosphorylated
to its active form tenofovir diphosphate (DP). TAF, how-
ever, is largely delivered unchanged into lymphocytes
and macrophages and then metabolised to tenofovir
and phosphorylated to active tenofovir DP. These differ-
ences allow a lower dose of TAF (25mg) than TDF
(300mg) and lead to much lower plasma concentrations
of tenofovir with TAF than with TDF and to much higher
tenofovir DP levels in lymphocytes and macrophages
[14,15]. This could be of importance since macrophages
and microglia are the main targets for HIV in the CNS.
One potential concern regarding TAF and its effect in
CNS is that TAF is a substrate for P-glycoprotein (P-gp),
which could theoretically decrease its CNS exposure
since substrates for P-gp are subject to active blood-
brain barrier efflux. TDF is also a substrate for P-gp, but
as mentioned, TDF is present in the systemic circulation
as tenofovir, which is not a P-gp substrate [16].
Treatment with ABC has been associated with higher
risk of cardiovascular disease in several studies [17–20].
The mechanism for this cardiotoxicity has not been fully
identified, but it has been shown that ABC can affect
inflammatory pathways [21], for example by increasing
neutrophil adhesion of endothelial cells, by interfering
with purine signalling pathways, by upregulation of pro-
inflammatory cytokine messenger RNA transcription, and
by increasing platelet activation [22]. In serum, high sen-
sitive CRP and IL-6 are markers that in some studies
have been increased in individuals on ABC [23]. If ABC
has the ability to drive inflammation in the periphery, it
could be hypothesised that ABC could be a driver of
CNS immune activation as well. ABC penetrates CSF in
adequate concentrations with an average CSF/plasma
ratio of 36% [24]. In a study investigating neurotoxic
effects in vitro of different antiretroviral drugs, ABC was
among the ones causing highest degree of neurotox-
icity, together with efavirenz, etravirine, nevirapine, and
atazanavir [25].
The main aim of the study was to investigate whether
switching to FTC/TAF from either FTC/TDF or ABC/3TC
would result in changes in CNS HIV infection as deter-
mined by CSF HIV RNA levels, degree of cellular and
humoral CSF inflammation, neuronal injury, and neuro-
cognitive performance.
Methods
Participants
For this small pilot study, participants were prospectively
included from the Department of Infectious Diseases,
Sahlgrenska University Hospital between May and
December 2016. To be eligible for the study, participants
were required to have had plasma HIV RNA less than 50
copies/mL for at least 12months and to have been on
continuous and stable ART for at least 18months with
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FTC/TDF or ABC/3TC and a third agent (protease inhibi-
tor, non-nucleoside reverse transcriptase inhibitor, or
integrase inhibitor). In addition, patients were required
to have undergone a lumbar puncture in the context of
the longitudinal Gothenburg HIV CSF study cohort
[26,27] at least three months prior to baseline in the
study. This was to determine if there were any signifi-
cant changes in the variables we were interested in dur-
ing unchanged ART. We did not include a control group,
but by including the pre-study lumbar puncture, partici-
pants were used as their own controls. Individuals with
conditions that could have an influence on CNS inflam-
mation, such as prior or ongoing neurological symp-
toms, severe neurocognitive impairment, and/or CNS
opportunistic infections or malignancies were excluded.
Study procedures
All participants underwent a lumbar puncture, venipunc-
ture, and testing of four neurocognitive domains with
the computerized CogState test at study entry (baseline).
They then switched their NRTI combination to FTC/TAF
and were followed with lumbar punctures, venipunc-
tures, and neurocognitive testing after three and
12months. FTC/TAF was dosed in accordance with the
Summary of Product Characteristics; 200mg/10mg once
daily when administered together with a ritonavir- or
cobicistat-boosted regimen and 200mg/25mg other-
wise. Ten patients received 200mg/10mg (8 on a
boosted protease inhibitor and two on elvitegravir) and
ten received 200mg/25mg (three on dolutegravir, three
on nevirapine, two on efavirenz, one on etravirine, and
one on rilpivirine). The study protocol was approved by
the Research Ethics Committee of the University of
Gothenburg (Dnr: 790-15) and the Swedish Medical
Products Agency. Participants were included after writ-
ten informed consent. The study is registered at
ClinicalTrials.gov, identifier number NCT02771054.
Methods
Blood CD4þ T-cell count and CSF cell counts were per-
formed in the local clinical laboratories using standard
methods. Plasma and CSF HIV-1 RNA was quantified
using RT-PCR (COBAS Taqman HIV-1 test, version 2,
Roche Diagnostic Systems) with a lower limit of quantifi-
cation of 20 copies/ml. Undetectable HIV RNA levels
were set as 18 copies/mL and detectable levels but <20
copies/mL were set as 19 copies/mL. CSF neopterin was
analysed with a commercially available immunoassay
(BRAHMS, Berlin, Germany). The upper normal reference
value was 5.8 nmol/L [28]. CSF b2-microglobulin was
measured by nephelometry (Dade-Behring Prospec).
Reference values were age-dependent as follows:
<1.2mg/l for individuals 49 years old and <1.8mg/L
for individuals >49 years of age.
Quantification of immunoglobulin G (IgG) and albu-
min in CSF and serum was performed by nephelometry
(Behring Nephelometer Analyser, Behringwerke AG,
Marburg, Germany). IgG index was used for determin-
ation of intrathecal IgG synthesis, and was defined as
(CSF IgG (mg/L)/serum IgG (g/L))/(CSF albumin (mg/L)/
serum albumin (g/L)). Reference value for IgG index was
<0.63. Albumin ratio was calculated as CSF albumin
(mg/L)/plasma albumin (g/L). Reference values were
<6.8 for individuals younger than 45 years and <10.2 for
individuals >45 years of age.
CSF NFL was measured by a sandwich ELISA method
with a lower limit of quantification of 50 ng/L (NF-lightVR
ELISA kit, UmanDiagnostics AB, Umeå, Sweden) at the
Clinical Neurochemistry Laboratory at the University of
Gothenburg. CSF NFL concentrations have been shown
to increase with normal ageing in healthy individuals
[7,12]. NFL concentrations were age-adjusted to the
median age of all participants of 54 years. Upper normal
reference value was 1121 ng/L, based on the antilog of
the log scale mean þ 2SD in 359 healthy controls [12].
Neurocognitive testing was performed with a compu-
terized cognitive test battery (CogStateTM, Melbourne,
Australia) that has been validated for HIV-infected indi-
viduals and for screening of HIV associated neurocogni-
tive disorder (HAND) [29–31]. Four different tests from
the CogState Brief Battery were used to assess five cog-
nitive domains: the detection test measured psycho-
motor function and attention, the identification test
assesses speed of information processing and attention,
the one-card learning test evaluated learning, and the
one back card memory test assessed working memory.
Estimated time for completing the test was 20–30min.
Scores were standardised to a z-score using a normative
data set and then a combined cognition score was cal-
culated in each individual by taking the average of the
standardised scores across all tasks. Each participant
served as their own control.
Statistical analysis
Continuous variables were log10 transformed wherever
appropriate for the tests used. Parametric methods were
used for statistical analysis. Differences between the two
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groups (ABC/3TC vs FTC/TDF) at baseline were com-
pared with unpaired t-tests. Longitudinal changes were
analysed with paired t-tests, p< .05 was considered stat-
istically significant. Correlations were determined with
Pearson correlation.
Results
A total of 20 participants (16 men and 4 women) were
included, 11 on ABC/3TC and nine on FTC/TDF. One par-
ticipant with a history of multidrug resistance was also
taking darunavir/ritonavir, raltegravir, and etravirine. All
other participants took only one additional antiretroviral
drug besides the two NRTIs. Patient characteristics are
presented in Table 1. Median (range) age for all partici-
pants was 54 (27–69) years. CD4þ T-cell count nadir and
at baseline were median (range) 170 (10–780) cells/mm3
and 620 (170–1100) cells/mm3, respectively. Participants
had been diagnosed with HIV for a median of 13.9
(range, 3.4–26.6) years ago and had been on ART for a
median of 10.4 (range, 2.3–19.9) years. There was a sig-
nificant reduction of age-adjusted CSF NFL between the
pre-study and baseline lumbar punctures, from median
721 (range 170–2135) ng/L to median 405 (range
246–2276) ng/L (p¼ .012, 95% confidence interval (CI)
reduction 8–46%) (Figure 1). At baseline, median treat-
ment duration in the FTC/TDF group was 6 (range 1–20)
years and 11 (range 3–20) years in the ABC/3TC group
(Table 1). At the time of the pre-study lumbar puncture,
2/9 in the FTC/TDF group had been on ART for less than
two years and 4/9 for less than five years compared to
0/11 and 2/11 in the ABC/3TC group. Otherwise there
were no significant changes in any of the other included
CSF biomarkers between the pre-study lumbar puncture
performed in median 12.6 (range 3.5–56.0) months
before initiation of the study and the baseline lumbar
puncture (Figure 1).
Figure 1. Longitudinal follow-up of cerebrospinal fluid (CSF) biomarkers. Results of all four lumbar punctures, from pre-study to 12months
of follow up, for participants switching from abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir
alafenamide fumarate (FTC/TAF). Lumbar punctures performed after participants switched to FTC/TAF are shaded with a light-grey back-
ground. (A) CSF neopterin, (B) CSF ß2-microglobulin, (C) IgG index, (D) albumin ratio, (E) age adjusted CSF NFL, and (F) results from the
neuropsychological testing with CogState. Dots depict median values and whiskers the interquartile ranges. Dashed lines indicate upper
normal reference values and the dotted line for CogState results indicates zero standard deviations.
Table 1. Characteristics of participants.
ABC/3TC FTC/TDF Total
Number 11 9 20
Sex (male:female) 8:3 8:1 16:4
Age in years 50 (30–69) 55 (27–67) 54 (27–69)
CD4 nadir (cells/mm3) 190 (40–357) 80 (10–780) 170 (10–780)
CD4 baseline (cells/mm3) 630 (170–1100) 610 (330–1000) 620 (170–1100)
Years since HIV-diagnosis 15 (3–21) 12 (5–27) 14 (3–27)
Treatment duration (years) 11 (3–20) 6 (1–20) 11 (1–20)
Additional antiretroviral drugs
-Protease inhibitor (number) 5 3 8
-NNRTI (number) 4 4 8
-Integrase inhibitor (number) 2 4 6
ABC/3TC: abacavir/lamivudine; FTC/TDF: emtricitabine/tenofovir disoproxil fumar-
ate; NNRTI: non-nucleoside reverse transcriptase inhibitor. Values presented as
median (range).
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At baseline, all but two participants (22 and 27 copies/
mL) had plasma HIV RNA levels <20 copies/mL and all but
one had CSF HIV RNA levels <20 copies/mL. The individ-
ual with elevated CSF viral load was on ABC/3TC and the
viral load was 55 (1.74 log10) copies/mL. Five participants
(25%) (four on ABC/3TC and one on FTC/TDF) had minor
CSF pleocytosis in the range 4–5 cells/lL. CSF neopterin
and CSF b2-microglobulin were elevated in 13 (65%) (8 on
ABC/3TC and 5 on FTC/TDF) and in seven (35%) (six on
ABC/3TC and one on FTC/TDF), respectively. IgG index
was above normal reference value in nine participants
(45%) (six on ABC/3TC and three on FTC/TDF). Albumin
ratio was elevated in one individual (5%) on TDF/FTC.
Median baseline values are presented in Figure 2.
There were correlations between baseline CSF HIV
RNA and CSF neopterin (r¼ 0.593, p¼ .006), CSF neo-
pterin and b2-microglobulin (r¼ 0.770, p¼ .001), and
CSF b2-microglobulin and CSF NFL (r¼ 0.446, p¼ .05).
Regarding the correlation between CSF HIV RNA and
CSF neopterin this is driven by one individual with very
high CSF neopterin and CSF HIV RNA.
All participants came to the visits at baseline and at
three months, but two participants did not complete the
12month follow up visit; one had died from heart failure
secondary to coronary artery disease and the second one
was lost to follow-up (moved abroad). Irrespective of
treatment group at baseline, no significant changes were
found after switching to FTC/TAF in any of the analysed
biomarkers: CSF and plasma HIV RNA levels, CSF cell
count, CSF neopterin, CSF b2-microglobulin, IgG index,
albumin ratio, or age-adjusted CSF NFL (Figure 1).
Individual changes from baseline to the 12month follow
up are presented in Figure 3. One participant in the FTC/
TDF-group had a substantial increase in CSF NFL at the
last follow-up, from 297 at the prior lumbar puncture to
6485ng/L. The patient was asymptomatic throughout the
study period and he has been adherent to his medication
for many years. A new lumbar puncture performed out-
side the study protocol one year later showed that CSF
NFL concentrations had returned to normal. No signifi-
cant changes were found in neurocognitive performance
between baseline and follow-up for any of the groups.
Discussion
In this small prospective study we found no significant
changes in intrathecal immune activation, CSF HIV RNA
levels, albumin ratios, degree of axonal injury, or
Figure 2. Baseline concentrations of (A) cerebrospinal fluid (CSF) neopterin, (B) CSF ß2-microglobulin, (C) IgG index, (D) albumin ratio, (E) CSF
NFL (neurofilament light chain protein), and (E) results from the neuropsychological testing with CogState for the eleven participants on abaca-
vir/lamivudine (ABC/3TC) (black dots) and the nine on emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (grey squares). There were no signifi-
cant differences between the groups. Bars indicate median and interquartile range. The dashed lines indicate upper normal reference values for
CSF neopterin, CSF ß2-microglobulin, IgG index, and CSF NFL, and the dotted line for CogState results indicates zero standard deviations.
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neurocognitive function within 12months after switch-
ing from either FTC/TDF or ABC/3TC to FTC/TAF as part
of a combination regimen. Theoretically, the effect of
TAF in the CNS could have been poor based on the fact
that CSF concentrations of tenofovir when administered
as TDF are low in most, and undetectable in some indi-
viduals [32,33], and when administered as TAF, CSF (and
plasma) tenofovir concentrations are even lower [34].
The lower tenofovir plasma concentrations and lower
CSF concentrations are a consequence of TAF not being
converted to tenofovir until after entry into the target
cells. On the other hand, concentrations are much
higher inside macrophages [14,15], where the drug is
activated and exerts its effect. Another important
explanation for low/undetectable CSF concentrations of
tenofovir when given as TAF is that TAF is a substrate of
P-gp and breast cancer resistance protein [16]. These
efflux proteins are localized not only in the intestines
but also in the blood-brain barrier, leading to decreased
CSF exposure. Despite low CSF concentrations and
active efflux out of the CNS, the results from our small
study suggest that TAF, as part of a combination
regimen, is as efficacious as ABC/3TC and FTC/TDF in
the CNS.
Another theoretical outcome could have been that par-
ticipants on a regimen containing ABC/3TC would have
an improvement of CSF inflammatory biomarkers, and
perhaps also of CSF NFL and neurocognitive function, but
no change in CSF HIV RNA levels after switching to FTC/
TAF, whereas participants on FTC/TDF would not. This
possibility is based on a number of studies demonstrating
an association between ABC use and cardiovascular
events. ABC has been associated with impaired endothelial
function, increased levels of circulating endothelial cells,
increased oxidative stress, augmented leukocyte–endothe-
lial cell interactions, and adherence of platelets to endo-
thelial cells or to leukocytes [35–38]. To our knowledge,
there are no published data on ABC and inflammation in
CSF/CNS. If ABC/3TC was more prone to cause CNS
inflammation than FTC/TDF, perhaps we would have seen
a significant difference for the biomarkers of immune acti-
vation at baseline between the groups.
The only significant change was a reduction of
median age-adjusted CSF NFL in individuals on FTC/TDF
Figure 3. Individual changes with the 95% confidence interval (CI) of cerebrospinal fluid (CSF) biomarkers from baseline to the 12month
follow-up: (A) CSF neopterin, (B) CSF ß2-microglobulin, (C) IgG index, (D) albumin ratio, (E) CSF NFL (neurofilament light chain protein), and
(E) results from the neuropsychological testing with CogState.
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from the pre-study to the baseline lumbar puncture,
from 721 ng/L to 374 ng/L (p¼ .02). One explanation for
this could be that participants on FTC/TDF had been on
their regimen for a shorter period of time compared
with those on ABC/3TC. Two out of nine and 4/9 in the
FTC/TDF group had been on ART shorter than two and
five years respectively, and for participants in the ABC/
3TC group the corresponding numbers were 0/11 and
2/11.
Despite the fact that most participants had been on
suppressive ART for many years, many had abnormal
CSF biomarkers of inflammation and neuronal injury.
The frequency we found is in the same range as previ-
ous studies. CSF neopterin levels are elevated in virtually
all untreated HIV-infected individuals, and even though
they decrease markedly after initiation of ART, approxi-
mately half will have slightly elevated CSF neopterin
even after several years [6,27]. The same pattern is seen
for the humoral immune system, with persistent mildly
increased IgG index [27]. CSF biomarkers of immune
activation strongly correlate with the axonal injury
marker CSF NFL; in this small study we also found a cor-
relation between CSF b2-microglobulin and CSF NFL.
Even if the majority of individuals on suppressive ART
have normal CSF NFL levels, concentrations are still
slightly higher than in HIV-negative controls [7], includ-
ing lifestyle-matched HIV-negative controls [39]. In add-
ition to the lumbar punctures and CSF biomarkers,
participants also underwent neurocognitive testing. No
significant changes were found in the test performances
during the study.
Strengths of this study are the prospective design,
with both short term and long term follow-up, and that
participants served as their own controls by inclusion of
a previous research lumbar puncture. One weakness is
the relatively small number of participants. This was a
pilot study with the aim of exploring whether we would
find any changes after switching to TAF; however, it is
unlikely that any differences of substantial clinical signifi-
cance would have been found in a larger study. Another
weakness is that we did not perform any ultrasensitive
quantification of CSF residual viral load, using, for
example, the single copy assay (SCA). Since CSF neo-
pterin concentrations, however, did not change, it is
unlikely that we would find changes in low-level HIV
RNA after switching regimens. It has previously been
shown that the presence of HIV RNA at very low levels
(detected with the SCA) is associated with higher CSF
neopterin levels [40] and that patients with CSF HIV RNA
levels above 2 copies/mL had higher levels of CSF
neopterin than those with undetectable CSF HIV RNA
(assay with lower quantification limit of 2 HIV RNA
copies/mL) [41].
In conclusion, we did not find any significant changes
in CSF viral loads, CSF biomarkers of inflammation or
axonal injury, or neurocognitive function when switching
to FTC/TAF from ABC/3TC or FTC/TDF in this small pilot
study. This is reassuring from a CNS perspective since
FTC/TAF is recommended in most treatment guidelines.
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